IQVIA’s (IQV) Outperform Rating Reaffirmed at Leerink Partners

Leerink Partners restated their outperform rating on shares of IQVIA (NYSE:IQV) in a report issued on Tuesday,Benzinga reports. Leerink Partners currently has a $248.00 price objective on the medical research company’s stock, down from their prior price objective of $260.00.

Several other analysts also recently commented on the company. Barclays dropped their price objective on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Jefferies Financial Group downgraded IQVIA from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $266.00 to $242.00 in a research note on Wednesday, July 24th. Morgan Stanley dropped their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Truist Financial dropped their price objective on IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Finally, Evercore ISI dropped their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Five investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Stock Up 0.2 %

NYSE:IQV opened at $191.33 on Tuesday. IQVIA has a 12-month low of $187.62 and a 12-month high of $261.73. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The firm has a market capitalization of $34.73 billion, a P/E ratio of 25.11, a P/E/G ratio of 1.98 and a beta of 1.51. The stock’s fifty day simple moving average is $225.08 and its 200-day simple moving average is $227.79.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The trade was a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Canada Pension Plan Investment Board grew its holdings in IQVIA by 6.6% during the second quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock worth $719,634,000 after purchasing an additional 211,653 shares during the period. Lazard Asset Management LLC grew its holdings in IQVIA by 0.9% during the first quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company’s stock worth $825,416,000 after purchasing an additional 30,014 shares during the period. Farallon Capital Management LLC grew its holdings in IQVIA by 3.1% during the second quarter. Farallon Capital Management LLC now owns 2,923,032 shares of the medical research company’s stock worth $618,046,000 after purchasing an additional 86,870 shares during the period. FMR LLC grew its holdings in IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the period. Finally, Capital Research Global Investors grew its holdings in IQVIA by 7.2% during the first quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company’s stock worth $540,882,000 after purchasing an additional 143,533 shares during the period. Institutional investors own 89.62% of the company’s stock.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.